Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacodynamics
5 evidence topics · 3 sources
Notch target gene inhibition in peripheral blood
“Target inhibition of Notch pathway related genes was observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Expression of Notch pathway-related genes in peripheral blood was measured as surrogate PD biomarkers for BMS-986115.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After 2 weeks of dosing at the highest tolerated doses of 1.2 mg QD and 1.5 mg QD, geometric mean relative expression of Hes1 was continuously inhibited by >50% below baseline, with peak inhibition of >80% (Fig. 2). Similarly, geometric mean relative expression of Deltex1 was continuously inhibited by greater than 45% for the entire dosing interval, with peak inhibition of >60% (Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the highest tolerated dose level of 4 mg BIW, geometric mean relative expression of Hes1 was inhibited by >75% for at least 48 h of the weekly dosing cycle and Deltex1 was inhibited by greater than 50%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exposure-response for safety in a pooled phase 1 to phase 3 population
| Adverse event of interest | Incidence, n (%) |
|---|---|
| Treatment-emergent serious adverse events | “49 (31.2)” |
| Grade 2+ hypophosphatemia | “47 (29.9)” |
| Grade 2+ fatigue | “43 (27.4)” |
| Grade 2+ nausea/vomiting | “31 (19.7)” |
| Grade 2+ diarrhea | “59 (37.6)” |
| Ovarian toxicity | “32 (50.0)” |
| Grade 2+ rash | “58 (36.9)” |
| Grade 2+ ALT elevation | “9 (5.7)” |
| Note | “Safety analysis population count was (N = 157) for all endpoints except ovarian toxicity (N = 64).” |
Exposure-response modeling of tumor volume and dose selection
Nonclinical pharmacology and toxicology
“Nonclinical experiments showed that BMS-986115 was effective as a single agent in the treatment of human T-ALL xenograft models, and demonstrated anti-tumour activity against 5 out of 7 solid tumour xenografts evaluated, including 3 breast, 1 NSCLC, and 1 pancreatic carcinoma. In animal studies, the main pharmacological toxicities included dose-dependent gastrointestinal (GI) toxicity, lymphoid depletion, and interruption of ovarian follicle maturation. Notch inhibitor mediated GI toxicity, which is characterized by goblet cell metaplasia throughout the intestines, is the result of on-target drug-induced differentiation of small intestinal and colonic progenitors to the secretory (goblet) cell fate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subjects were required to have an adequate lipid profile as increases in triglycerides were seen in the multiple dose rat study with BMS-986115.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote